JP7745323B2 - ハロゲン化抗菌ペプトイド - Google Patents

ハロゲン化抗菌ペプトイド

Info

Publication number
JP7745323B2
JP7745323B2 JP2021564976A JP2021564976A JP7745323B2 JP 7745323 B2 JP7745323 B2 JP 7745323B2 JP 2021564976 A JP2021564976 A JP 2021564976A JP 2021564976 A JP2021564976 A JP 2021564976A JP 7745323 B2 JP7745323 B2 JP 7745323B2
Authority
JP
Japan
Prior art keywords
poly
compound
substituted glycine
halogen
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532317A (ja
JP2022532317A5 (https=
Inventor
モルカノバ，ナタリア
ジェンセン，ハバード
バロン，アンネリセ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxwell Biosciences Inc
Original Assignee
Maxwell Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxwell Biosciences Inc filed Critical Maxwell Biosciences Inc
Publication of JP2022532317A publication Critical patent/JP2022532317A/ja
Publication of JP2022532317A5 publication Critical patent/JP2022532317A5/ja
Priority to JP2024152955A priority Critical patent/JP2024170542A/ja
Application granted granted Critical
Publication of JP7745323B2 publication Critical patent/JP7745323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021564976A 2019-04-30 2020-04-30 ハロゲン化抗菌ペプトイド Active JP7745323B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024152955A JP2024170542A (ja) 2019-04-30 2024-09-05 ハロゲン化抗菌ペプトイド

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962841227P 2019-04-30 2019-04-30
US62/841,227 2019-04-30
PCT/US2020/030890 WO2020223581A1 (en) 2019-04-30 2020-04-30 Halogenated antimicrobial peptoids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024152955A Division JP2024170542A (ja) 2019-04-30 2024-09-05 ハロゲン化抗菌ペプトイド

Publications (3)

Publication Number Publication Date
JP2022532317A JP2022532317A (ja) 2022-07-14
JP2022532317A5 JP2022532317A5 (https=) 2023-04-26
JP7745323B2 true JP7745323B2 (ja) 2025-09-29

Family

ID=73029339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021564976A Active JP7745323B2 (ja) 2019-04-30 2020-04-30 ハロゲン化抗菌ペプトイド
JP2024152955A Pending JP2024170542A (ja) 2019-04-30 2024-09-05 ハロゲン化抗菌ペプトイド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024152955A Pending JP2024170542A (ja) 2019-04-30 2024-09-05 ハロゲン化抗菌ペプトイド

Country Status (5)

Country Link
US (1) US20220213144A1 (https=)
EP (1) EP3962925A4 (https=)
JP (2) JP7745323B2 (https=)
CA (1) CA3138644A1 (https=)
WO (1) WO2020223581A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002696A (es) * 2019-09-03 2022-07-21 Maxwell Biosciences Inc Composiciones de peptoides antivirales.
CN112698030B (zh) * 2020-12-10 2022-02-01 丹娜(天津)生物科技股份有限公司 一种基于酶联免疫法检测新型冠状病毒抗体的试剂盒
EP4047012A1 (en) * 2021-02-17 2022-08-24 Université de Bordeaux Antimicrobial cationic peptoid and n-subtituted peptidic copolymers, preparation and uses thereof
US20250121121A1 (en) * 2021-06-25 2025-04-17 Maxwell Biosciences, Inc. Substrates modified with peptoid-loaded microgels for resistance to bacterial colonization
US20240316141A1 (en) * 2021-07-16 2024-09-26 The Board Of Trustees Of The Leland Stanford Junior University The Use of Thiourea and Thiourea Derivatives As Potentiators of Antibacterial Activity of Peptoids
US20250268976A1 (en) 2024-02-23 2025-08-28 Maxwell Biosciences, Inc. Broad-spectrum peptoids for treatment or prevention of wound infections, and compositions and methods of use thereof
US20250268809A1 (en) 2024-02-23 2025-08-28 Maxwell Biosciences, Inc. Broad-spectrum peptoids for oral and dental hygiene, and compositions and methods of use thereof
WO2025178965A1 (en) 2024-02-23 2025-08-28 Maxwell Biosciences, Inc. Peptoids for treating filoviridae infections
US20250282821A1 (en) 2024-03-08 2025-09-11 Maxwell Biosciences, Inc. Lipopolysaccharide-binding peptoids, and compositions and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511077A (ja) 2008-02-08 2011-04-07 ノースウエスタン ユニバーシティ 選択的ポリ−ｎ−置換グリシン抗生物質

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511474D0 (en) * 1995-06-07 1995-08-02 Ciba Geigy Ag Antiviral peptoid compounds
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
WO2010098843A2 (en) 2009-02-24 2010-09-02 New York University Peptoid oligomers, pharmaceutical compositions and methods of using the same
US9938321B2 (en) 2013-03-13 2018-04-10 New York University Cyclic peptoid oligomers, pharmaceutical compositions and methods of using the same
US9770504B2 (en) * 2013-05-03 2017-09-26 The Board Of Regents Of The University Of Texas System Generating peptoid vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511077A (ja) 2008-02-08 2011-04-07 ノースウエスタン ユニバーシティ 選択的ポリ−ｎ−置換グリシン抗生物質

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bioorganic and medical chemistry letters，2018年，Vol.28，p.170-173
Med. Chem. Commun.，2016年，Vol.7，p.799-805
Med. Chem. Commun.，2017年，doi:10.1039/c6md00648e

Also Published As

Publication number Publication date
CA3138644A1 (en) 2020-11-05
JP2022532317A (ja) 2022-07-14
EP3962925A4 (en) 2023-08-23
WO2020223581A1 (en) 2020-11-05
JP2024170542A (ja) 2024-12-10
US20220213144A1 (en) 2022-07-07
EP3962925A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
JP7745323B2 (ja) ハロゲン化抗菌ペプトイド
JP7360419B2 (ja) 安定化抗微生物性ペプチド
Clark et al. Cylindrical β-sheet peptide assemblies
JP7432640B2 (ja) 感染症を治療するステープル化細胞内ターゲティング抗微生物ペプチド
Gutsmann et al. New antiseptic peptides to protect against endotoxin-mediated shock
JP2011511077A (ja) 選択的ポリ−ｎ−置換グリシン抗生物質
CN109415411B (zh) 表现出抗革兰氏阴性菌的抗微生物活性的断开或折叠的螺旋肽或肽类似物及其用途
Volejníková et al. Antimicrobial peptides prevent bacterial biofilm formation on the surface of polymethylmethacrylate bone cement
Smirnova et al. Indolicidin analogs with broad-spectrum antimicrobial activity and low hemolytic activity
Azoulay et al. Assembly of cationic and amphiphilic β-sheet FKF tripeptide confers antibacterial activity
Glossop et al. Battacin-inspired ultrashort peptides: nanostructure analysis and antimicrobial activity
Gururaja et al. Candidacidal activity prompted by N-terminus histatin-like domain of human salivary mucin (MUC7)
Lohan et al. Systematic study of non‐natural short cationic lipopeptides as novel broad‐spectrum antimicrobial agents
Domalaon et al. Dilipid ultrashort cationic lipopeptides as adjuvants for chloramphenicol and other conventional antibiotics against Gram-negative bacteria
WO2015144928A1 (en) Antimicrobial peptide dendrimers
EP3443078A1 (en) Antimicrobial compositions
Qi et al. Discovery, synthesis, and optimization of teixobactin, a novel antibiotic without detectable bacterial resistance
Hasan et al. Chain-end modifications and sequence arrangements of antimicrobial peptoids for mediating activity and nano-assembly
ES2475765T3 (es) P�ptido antimicrobiano, formas ramificadas del mismo y su uso en el tratamiento de infecciones bacterianas
EP3313862A1 (en) Broad-spectrum anti-infective peptides
Dong et al. Structure-activity analysis and biological studies of chensinin-1b analogues
WO2018231058A2 (en) Antimicrobial peptides and admixtures thereof showing antimicrobial activity against gram-negative pathogens
Nyembe et al. Review: structure-activity relationship of antimicrobial peptoids. Pharmaceutics 2023; 15: 1506
Saroj et al. Augmentation of Antimicrobial Activity of Spiniferin by Introducing an Arginine Residue Toward Its Amino Terminus: A Possible Role of Cation− π Interaction
Schmidt et al. Lipid Environment of Aquaporin Z

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250915

R150 Certificate of patent or registration of utility model

Ref document number: 7745323

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150